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symptoms from the Centers for Disease Control and Prevention
(CDC) and the World Health Organization (WHO) continues to

Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, led to

change. As COVID-19 is a rapidly evolving disease, clinical experience

the spread of Coronavirus Disease 2019 (COVID-19) in December

so far concludes that people aged >65 years are at a higher risk of

2019 from Wuhan, China, to most of the world. COVID-19 is a respi-

severe illness. Underlying medical conditions, such as lung and heart

ratory disease with wide spectrum of symptoms ranging from mild to

diseases, immunodeficiency, obesity, diabetes, and kidney and liver

severe and involving many different organ systems. The list of

diseases, increase mortality risks.1 Among 4103 patients in New York
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City between 1 March, and 2 April, 2020, hospitalization risks were
greatest for those aged ≥75 years, with body mass index >40, and
with heart failure.2 New syndromes are still being described, including
skin symptoms and systemic inflammatory syndromes, such as sepsis
in adults and a Kawasaki-like syndrome in children.3-5
While the SARS-CoV-2 genome is 96% identical to bat coronavirus and shares 79.6% sequence identity to SARS-CoV,6 the
COVID-19 mutant virus is believed to have a different diagnosis and
prognosis from the precedent forms. SARS-CoV-2 has a four-phase
infection paradigm. Phase 1 includes cell invasion and viral replication
through binding of the viral spike protein to a cell surface receptor
called ACE2.7 Phase 2 includes replication of SARS-CoV-2 in the lung
and immune system activation. In more severe cases, phase 3 includes
pneumonia, and in the most severe cases, phase 4 includes acute
respiratory distress syndrome, a cytokine storm, sepsis, and multiple
organ failure. A cytokine storm is characterized by cascades of inflammatory cytokines being released systemiclly, including IL-6, which has

Significance statement
Regenerative medicine is uniquely positioned to provide
advanced organoid models to understand the infection
mechanism of, identify patients at risk for, and develop ways
to prevent COVID-19, as well as to introduce innovative
treatments that have immunomodulatory and regenerative
properties. The Regenerative Medicine Manufacturing Society (RMMS) and STEM CELLS Translational Medicine (SCTM)
collaborated to create a platform on the STEM CELLS Portal
(https://stemcellsportal.com/regenerative-medicine-covid19-resources) for sharing regenerative medicine resources
to address the COVID-19 pandemic in three areas: models,
cell therapies, and technologies. This information will be
made publicly available and developed further by RMMS in
future webinars and perspective articles.

been tied to increased damage in the lungs and other organs.8,9 Current standard of care treatment for COVID-19 patients across these
phases can be found on the CDC website, where guidelines are provided for the medical management of COVID-19 and have been publi-

Organoids are self-organizing cellular three-dimensional (3D) struc-

shed by the National Institutes of Health (NIH).10

tures in an extracellular matrix (ECM). Organoid technology is a pow-

Regenerative medicine is uniquely poised not only to provide

erful tool for disease modeling in vitro, as they can replicate essential

solid understanding of the infection mechanism and ways to prevent

structural and functional aspects of organs in a dish. Alveolar

it, but also to introduce innovative treatments other than drugs.

organoids could improve our understanding of the antiviral inflamma-

Figure 1 captures the phases and clinical symptoms of COVID-19, as

tory response and expedite the development of therapies.11 Lung

well as innovative ways to model and treat the disease, including

organoids also offer a way to study differences in how the virus

organoids, immunomodulatory effects, and regenerative effects.

infects the lung cells of different patients and how patients might

F I G U R E 1 Different approaches for fighting COVID-19. Illustrated in this graphic figure are (a) phases and clinical symptoms of COVID-19,
(b) models for COVID-19, (c) advanced organoid systems for drug screening and personalized medicine, and (d) regenerative medicine approaches
for treating COVID-19
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respond to tailored treatments. Other organ-specific organoids, such

available to researchers by public repositories. The Tg(FOXJ1-ACE2)

as the kidney or liver, can be applied to developing therapies to pre-

1Rba is from the Mouse Mutant Research and Resource, stock

vent COVID-19-related organ failure.

MMRRC:066719, and the B6.Cg-Tg(K18-ACE2)2Prlmn/J mouse is

The immunomodulatory effect of stem cell therapies has gained a
rapidly growing interest during the COVID-19 pandemic. At this writ-

available from The Jackson Laboratory, JAX:034860. Their response
to SARS-CoV2 is not clear at this time.

ing, there are 94 clinical trials listed on ClinicalTrials.gov that are

Compared with mouse models, Syrian hamsters present more

related to stem cells used for COVID-19 therapy. Mesenchymal stro-

human-like disease symptoms and pathogenesis with viruses like

mal/stem cells (MSC) have the ability to secrete a variety of endo-

Ebola,20 and their immune responses are more similar to humans.21

somes and factors that reduce damaging inflammation, and several

Studies of SARS-CoV in Syrian hamsters noted viral replication in the

clinical trials involve administration of MSCs to COVID-19 patients.12

lungs with clearance in 7 days; however, the hamsters did not pro-

Intravenous MSC infusion showed a reduction in inflammatory cell

gress to ARDS.22 While Syrian hamsters clearly have their niche in

types and cytokines, such as tumor necrosis factor, and an increase in

infectious diseases, there are also limitations to their use. Species-

anti-inflammatory cytokines, such as interleukin 10 (IL-10). Gene

specific reagents such as antibodies are scarce. Still, while the Syrian

expression profiles showed that MSCs were angiotensin-converting

hamster is a promising model for the study of COVID-19, their limited

enzyme 2-negative (ACE2-) and transmembrane serine protease

commercial availability and widespread use present practical limita-

2-negative (TMPRSS2-), which indicated MSCs were resistant to

tions in their high throughput use.

COVID-19 infection.13 MSCs have also been shown to assist with
sepsis14,15 and reduce inflammation.16

Ferrets are good models for respiratory diseases, as their lung and
airway physiology are close to humans. Unlike rodents, ferrets cough

The goals of regenerative medicine—to repair, regenerate, and

and sneeze, making them a useful model of disease transmission.

restore missing function or tissue—might drive the investigation of

When infected with SARS-CoV-2, ferrets have elevated temperatures,

several regenerative therapies for COVID-19-recovered patients. In a

lethargy, and appetite loss but do not progress to ARDS. There are

retrospective, observational study on critically ill patients with SARS-

also few research facilities capable of working with ferrets, which

17

CoV-2 pneumonia,

the authors reported that most patients had

organ function damage, including 67% with acute respiratory distress

have complicated animal husbandry requirements and a limited commercial supply.23

syndrome (ARDS), 29% with acute kidney injury, 29% with cardiac

Each animal model offers advantages that will be useful, not only

injury, and 29% with liver dysfunction. Moreover, type II pneumocytes

for the testing of therapies, but also for understanding related co-mor-

in the lung are a major target of SARS-CoV, propagating new virus

bidities. Interested readers are referred to this excellent reference,

and suffering widespread damage. Type II pneumocytes express ACE2

which compares 10 different animal models in the search for the best

and associated enzymes transmembrane protease serine 2 (TMPRSS2)

model to study COVID-19.24

and Cathepsin L (CTSL).18 Lung progenitor cells (CD34 + Oct4+) can
be preferentially infected by SARS-CoV (2003 version) compared with
more mature pneumocytes.19 Taken together, these findings mean
that as COVID-19-infected lungs try to replace damaged and dead

3 | A D V A N C E D O R G A N O I D SY S T E M S F O R
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lung cells, the replacement stem and progenitor cells may also be
targeted by the virus in a one-two punch. This may be behind the long

Organoids can model organ function in-vitro, providing a more acces-

periods of time it takes for patients to recover, as well as the lung

sible, faster, and higher throughput screening tool than in vivo models.

scarring that may reduce lung capacity, perhaps permanently for some

There are a few methods to engineer organoids, including manual 3D

patients. After the pandemic is past, there will be a lasting population

culture, liquid handling, or 3D bioprinting. All of these methods can

of patients who need long-term therapy to regain lost lung function.

use ECM in the process, which results in cell assembly that recapitu-

Any treatment that can boost the regenerative power of lung tissues

lates organ function on a small scale and can help model different clin-

by replacing these critical stem cells will help a large new patient

ical features of COVID-19.25 Using organoids to model organ function

population.

and infection by the SARS-CoV-2 virus can be a valuable tool to
gather more insights on its viral tropism and pathogenesis, as well as
serve as a platform to find potential treatment strategies for COVID-

2 | SM A L L A N I M A L M OD E LS F OR
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19. While initial studies with SARS-CoV-2 have used Vero E6 cells,
using models of the lung, heart, kidney, and intestine can be crucial to
new therapies.

The use of the standard laboratory mouse has been limited because

Lung organoids have previously been used to model infections by

of the mismatch in the ACE2 receptor sequence between mouse and

different pathogens. Hui et al. developed human lung organoids that

humans. Mice genetically engineered to carry the human ACE2 gene

recapitulate the bronchial airway, including cilia, goblet cells, club cells,

for research on SARS-CoV are rapidly being assessed for their use in

and basal cells.26 They then successfully infected these organoids with

the study of COVID-19. Two models, the B6.Cg-Tg(K18-ACE2)

the influenza virus, analyzing replication competence, tissue tropism,

2Prlmn/J mice and the Tg(FOXJ1-ACE2)1Rba mice, have been made

and host responses. Their results were comparable to those observed

8
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in human ex vivo bronchus cultures, offering a viable alternative for
modeling viral infections in the lung.
Similarly, Monteil et al used SARS-CoV-2-infected human kidney
organoids to investigate the effectiveness of human recombinant soluble ACE2 (hrsACE2) in inhibiting viral growth.27 Liver organoids were
also utilized to investigate how this tissue is infected and damaged by
SARS-CoV-2. Zhao et al found evidence to support the hypothesis
that COVID-19 patient liver damage might be resultant from cholangiocyte injury and consequent bile acid accumulation caused by
the viral infection.28 These results indicate that organoids are a powerful tool in understanding mechanisms through which SARS-CoV-2
affects liver tissue.
Although cardiac organoid infection by the SARS-CoV-2 virus has
not been characterized, cardiac organoids could be a feasible platform
for use in COVID-19 drug screening. Mills et al, for example, developed a high-throughput bioengineered human cardiac organoid platform, using it to screen 105 small molecules with regenerative
potential.29 These organoids could also be used to study how the
heart is affected by COVID-19.
The intestine is another target organ for the SARS-CoV-2 virus,
with a high expression of ACE2 in intestinal enterocytes. Lamers et al.

F I G U R E 2 Advanced organoid tissue chips for evaluating organ
toxicity of COVID-19 drugs. This figure shows how testing could be
performed using organoid tissue chips to screen potential toxicity in
drug candidates

developed human small intestinal organoids (hSIOs) that were readily
infected by SARS-CoV and SARS-CoV-2 viruses.30 Their study indi-

the ability to test so many compounds across these different organ

cated enterocytes as the target cell for infection in the intestine, dem-

systems, which could be created for thousands and thousands of

onstrating that intestinal organoid cultures can be a key method for

patients. This idea is in fact being taken to a new level by the NIH,

better understanding viral biology.

which has deployed funding opportunities for clinical trials on a chip.

Immune organoid culture can also contribute to understanding

The future will harness these tissue chips and use large data reposito-

COVID-19 immune responses.31 Organoids are a useful tool to inves-

ries to essentially perform clinical trials using patient-derived organoid

tigate and characterize organ function and disease progression, and

models.

they should be further explored as a high-throughput, highly specific
platform for COVID-19 drug screening.
Human in vitro tissue-on-a-chip platforms enable the direct use
of human heart cells to evaluate potential effectiveness of existing or

4 | RE G EN M E D T H E R A P I E S F O R
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new COVID-19 drugs (Figure 2). Additionally, using cells from a
diverse patient population, including both sexes, may help classify the

Patients

cardiovascular and pulmonary risk of COVID-19 drugs. Additionally,

proinflammatory cytokine levels, including increased IL-6 levels that

there is need to screen repurposed drugs for COVID-19 for toxicity,

can be part of the cytokine storm or cytokine release syndrome

and an excellent review has evaluated current therapeutic drugs for

(CRS).35 CRS is not new to the regenerative medicine industry. Chime-

32

the treatment of COVID-19 patients.

suffering

from

severe

COVID-19

have

increased

ric antigen receptor T-cell therapy (CAR-T), the first FDA-approved cell

Tissue chips using lung airway epithelium that express high levels

therapy, can elicit CRS. Since the beginning of the current pandemic,

of ACE2 and TMPRSS2 have been used to screen repurposed drug

the regenerative medicine industry has rapidly pivoted to translate the

candidates for inhibition of SARS-CoV-2 viral entry.27 When used to

lessons learned from mitigating CRS in CAR-T therapy to COVID-19.36

assess seven clinically approved drugs (chloroquine, arbidol, tor-

Recent results from the Randomized Evaluation of COVID-19 Therapy

emifene, clomiphene, amodiaquine, verapamil, and amiodarone), only

(RECOVERY) trial (ClinicalTrials.gov Identifier: NCT04381936) con-

toremifene and amodiaquine were found to inhibit viral entry. These

firmed that patients hospitalized with COVID-19 receiving dexametha-

results suggested that human tissue chip technology screening assays

sone (a corticosteroid medication) resulted in lower 28-day mortality

could be used to study human disease pathogens and expedite drug

among those receiving either mechanical ventilation or oxygen alone.37

33

repurposing.

Figure 2 highlights how organ toxicity of COVID-19

This study supports the tremendous benefits of large randomized stud-

drugs could be evaluated using these organoid tissue chips, where

ies in evaluating interventions for COVID-19. Previous clinical data did

advances in connecting these organ chips to achieve multi-tissue

not support the use of corticosteroid treatment for COVID-19-related

34

interactions will be important to detect unanticipated drug toxicity.

lung injury.38 Therefore, there is an emergent need for more large ran-

Taken together, employing an advanced organoid tissue chip can

domized trials, such as RECOVERY, to develop new treatments for

reduce the cost and time needed to develop new treatments, due to

COVID-19-associated CRS and ARDS.
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MSCs are the leading potential allogeneic cellular therapy candi-

Rather than quashing immune responses, boosting immune

date for ARDS and CRS.39 Once at the site of infection, MSCs release

responses using natural killer (NK) cells also has been proposed as a

anti-inflammatory cytokines and act through cell-cell contact to help

treatment for severe COVID-19. Celularity Inc. recently received FDA

regulate the local environment. Early studies in China have demon-

approval to initiate a trial in 86 COVID-19 patients. Celularity’s pla-

strated the efficacy of MSCs in COVID-19 patients and some have

cental stem cell-derived NK cells may be able to target and eliminate

already been published.13 Outside of China, promising results in small

virally infected cells; however, there are risks that NK cells may add to

cohorts have already shown some success and been announced.

COVID-related inflammation and that they might not be able to

Pluristem Therapeutics showed that infusion of placenta-derived

detect which cells are infected.48

“mesenchymal-like cells” in COVID-19 patients with ARDS on

Overall, regenerative medicine offers tremendous hope for

mechanical ventilation led to improvements in four of six patients.40

treating COVID-19, and initial clinical trial results are promising. How-

Under emergency use, RESTEM recently showed promising results

ever, properly designed and conducted clinical trials, with appropriate

from infusion with experimental umbilical cord lining-derived stem

enrollment, controls, and evaluation, are still needed.

cells in three COVID-19 patients with ARDS. On the basis of these
results, the RESTEM has received FDA approval for a 60-patient
phase I/II clinical trial.41 The University of Miami Medical School also
has FDA approval to test cryopreserved allogenic umbilical cord stem
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cells on 12 COVID-19 patients.42 In terms of the allogeneic approach
with bone-marrow derived MSCs, Remestemcel-L, developed by

With great challenges come great opportunities for the scientific com-

Mesoblast, has an encouraging potential after 9 of 12 moderate to

munity. Several resources have been made available to combat

severe COVID-19 patients successfully came off ventilators within

COVID-19 over a short period of time since the deceleration of the

10 days of two infusions.43 Athersys also released positive 28-day

pandemic. In the future, we envision doing more with less, fully auto-

data with 1-year follow-up on an ARDS trial using MultiStem, which

mating standardized workflows, using artificial intelligence (AI) to mine

showed improvement in survival and improvements in ventilator

data and develop learning and predictive algorithms and using modu-

dependency. As a result, the MultiStem has been given fast-track des-

lar GMP environments to optimize manufacturing processes.

ignation by the FDA, and MACOVIA, a pivotal phase II/III trial will

Social distancing requirements will be imposed on laboratories in

enroll ~400 COVID-19 patients. The FDA also recently approved a

response to the COVID-19 pandemic, so automation will improve the

phase II single-arm study for Hope Biosciences (Houston, TX) to enroll

standard workflow in the laboratory and minimize the use of people

75 high-risk participants using autologous, adipose-derived MSCs.44

and personal protective equipment. Recent publications discuss auto-

In addition to these trials, more than 200 additional MSC-related clini-

mation and standardization of processing for a potential miRNA

cal trials for COVID-19 have been registered on ClinicalTrials.gov as

marker candidates.49,50 For instance, the Revos Tissue Processor

of August 10, 2020. This fairly extensive clinical effort to develop an

(Thermo-Fisher) and high resolution slide scanners, such as those from

MSC therapy includes sources from umbilical cord, bone marrow, adi-

3DHISTECH, reduce labor time and maintain efficiency during

pose tissue, and dental pulp. Leveraging some early positive results,

reduced staff schedules. It will also be advantageous to pair these

more extensive well-designed clinical trials are ongoing, which will be

technologies with archiving solutions like the ARCOS platform from

critical in establishing the effects of MSC treatments on COVID-19

EPREDIA for efficient data storage and recovery and potentially to be

patient survival and accelerated recovery.

combined with machine learning and predictive algorithms. With

Regulatory T cell (Treg) transfusion may also be efficacious

remote access to images, research can continue even during limited

against COVID-19 associated CRS. Like MSCs, Tregs reduce immune

access to a facility. Building upon this, the adoption of cloud-based AI

responses and play a role in the prevention of autoimmunity, allergy,

solutions further enables remote access to data. One such ecosystem,

organ

a spin-off from Memorial Sloan Kettering Hospital, has assisted in

transplant

rejection,

and

other

inflammatory

immune

responses.45 Allogeneic Treg therapy has been explored as a treat-

accelerating biomarker discovery by PAIGE.AI.51

ment for amyotrophic lateral sclerosis. Recently, Cellenkos46 submit-

Cell therapies production models are moving toward closed sys-

ted a clinical development proposal to the Biomedical Advanced

tems to reduce contamination risks. Closed bioreactors are gaining

Research and Development Authority (BARDA) for phase I/II clinical

traction for cell expansions steps. Closed, modular cGMP cell produc-

trials for COVID-19 using cord blood Tregs.

tion environments that can enclose all the cell production steps from

Capricor Therapeutics recently announced that treatment with

start to finish are available and will be implemented in a post-COVID-

allogeneic cardiosphere-derived cells led to four of six COVID-19

19 world. These systems have flexibility to be configured in non-GMP

patients being removed from mechanical ventilation within 1-4 days

space and validated in weeks. The clonability of the system means

post-transfusion. As a result of this success, the US FDA has approved

that once conditions are optimized for production of the most potent

the company’s expanded access protocol allowing for treatment of

cell product (O2, CO2, temperature, humidity), those same conditions

twenty additional COVID-19 patients.

47

While early results are very

can be verifiably reproduced anywhere in the world. This adds scien-

promising, these preliminary reports lack proper control arms and pla-

tific reproducibility and reliability to distributed COVID-19 organoid

cebos, and further trials are necessary.

and cell therapy production models.
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A new potential resource is the use of commercially available

Center at Stanford, with other international partners and collaborators,

small satellites in low Earth orbit to be used as a microgravity research

which provides a continuously updated free database on interventions for

platform, in conjunction with tissue chip/lab-on-a-chip technology

COVID-19. BioCentury has a COVID-19 Resource Center71 with an infor-

and/or microfluidic devices such as what the National Center for

mation portal on COVID-19 therapies and vaccines (clinical and preclini-

Advancing Translational Science is working on in collaboration with

cal), COVID-19 trial timeline, diagnostics, status of regulatory meetings,

the Defense Advanced Research Projects Agency and the Food and

resources for researchers, and a COVID-19 research gateway where com-

52

Drug Administration.

Companies and research institutions are

panies and researchers are provided an intake form to submit their latest

finding considerable value in exploring the effects of the space envi-

advances on compounds, diagnostics, preclinical assays, clinical trial

ronment on human health, pharmaceuticals, biotechnology/bioengi-

designs, protocols, sites, data or data-sharing resources, and inquiries

neering, and advanced manufacturing. In fact, studies have shown

about COVID research and development.

that microgravity can cause various pathogens to become more

The Regenerative Medicine Manufacturing Society (RMMS) and

virulent,53 which has a genetic component,54 and this could be used

STEM CELLS Translational Medicine (SCTM) have created a page on the

to develop accelerated disease progression models in organoids

STEM CELLS Portal for regenerative medicine resources in the fight

infected with the SARS-CoV-2 virus. The space environment has

against COVID-19. This page provides a COVID-19 Resource Submis-

properties not found in terrestrial environments, which includes

sion Page72 for scientists (academic, industry, government, non-profits,

microgravity, hard vacuum, and space radiation. These properties have

etc.) to highlight regenerative medicine resources directed against

surprising effects on cellular and molecular processes. Opportunities

COVID-19 in three areas: (a) models, (b) cell therapies, and

exist for elucidating molecular mechanisms in microgravity, studying

(c) technologies. These resources will be presented in a redacted format

complex fluid dynamics, testing materials, analyzing proteins and large

(type of regenerative medicine resource / institution / resource descrip-

molecules, and advancing the science of nanofluidics and biotechnol-

tion) on the Regenerative Medicine COVID-19 Resources Results

ogy. For example, Orbital Transports, Inc., is developing solutions for

Page73 and shared with RMMS working group co-leads to continue

performing cellular and molecular research on small satellites by using

meaningful discussions within the working groups and also to plan

a suitably sized bioreactor, tissue chip/lab-on-a-chip technology,

future webinars and perspective articles to disseminate these important

and/or microfluidic devices. This will enable new opportunities for

regenerative medicine resources to the entire scientific community.

space-based research that can be conducted without human interven-

Those wishing to become involved in RMMS working groups are

tion, and thus, free the scientist from crew time and other limitations

encouraged to visit our website (http://regenmedmanufacturing.org/

inherent to the mission of the International Space Station.

membership/) and sign up to be a member.

The world’s leading journals are providing free access to COVID-

The scientific community continues to work diligently and coop-

19-related papers and resources. The New England Journal of Medicine

eratively to combat COVID-19 and the coronavirus. Through collabo-

has a COVID-19 landing page that compiles all of their COVID-19 con-

ration, reliance on real-world evidence, and a willingness to roll up our

55

tent.

The Lancet also has a resource center focused on COVID-19 and

sleeves and get to work, we will overcome this pandemic together.

provides free access.56 The journal Nature’s newsletter, Nature Briefing,
is a weekly gathering of the latest information.57 COVID-specific literature web search engines, such as COVID Scholar,58 have also appeared.
Utilizing these free reliable resources will give you the latest, substanti-
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ated scientific developments under way to combat COVID-19.
The US FDA has done an outstanding job in response to COVID-

Regenerative medicine is poised to make a true difference in the fight

19. The FDA has fast-tracked potential treatments (~60 day review)

against COVID-19. We have reviewed some of the advances in

and has been very responsive in approving Emergency Use Authoriza-

organoid systems to model COVID-19 symptoms that could be used

tions. They also have a dedicated specific resources: Coronavirus Dis-

for developing new treatments or screening at-risk patients. We have

ease 2019 (COVID-19),59 Emergency Use Authorizations,60 and

also covered some of the effects regenerative medicine-based thera-

Coronavirus Treatment Acceleration Program (CTAP).61 Additional

pies may have on treating COVID-19-related symptoms, such as

resources to get the complete picture of the developments taking place

immunomodulatory effects or even regenerative effects. We have dis-

are also available at the following organizations: World Health Organi-

cussed technologies and resources that are currently available to con-

zation (WHO),62 Centers for Disease Control and Prevention (CDC),63

front COVID-19. It is times like these when we must all come

John Hopkins,64 Chinese CDC,65 and Gates Notes.66 The Atlantic has

together, share our talents and resources, and develop the best

67

developed The COVID Tracking Project

to focus on the incredibly

important topic of testing and compiles the most accurate data avail-

methods, technologies, and capabilities to address global health
challenges.

able. Eva Garland Consulting LLC has done a great job of compiling and
continuously updating the grants opportunities.68 CellTrials.org also
69

provides a free report on all registered COVID-19 trials.
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